Prognostic Value of Clinical Staging According to TNM in Patients With SCLC: A Real-World Surveillance Epidemiology and End-Results Database Analysis [0.03%]
基于SEER数据库的广泛期小细胞肺癌预后分析及TNM分期的临床价值评估
Edurne Arriola,José Manuel Trigo,Amparo Sánchez-Gastaldo et al.
Edurne Arriola et al.
Introduction: SCLC is one of the most lethal malignancies. Classically, staging has been performed using a dual classification distinguishing limited from the extensive stage. This study aimed to evaluate the prognostic v...
Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005) [0.03%]
亚洲多中心晚期KRAS突变型非小细胞肺癌临床特征和预后分析（ATORG-005）
Jiyun Lee,Aaron C Tan,Siqin Zhou et al.
Jiyun Lee et al.
Introduction: Whereas interpatient heterogeneity in clinical characteristics and treatment outcomes of NSCLC harboring a KRAS mutation is recognized, the characterization of these patients in Asia has been limited. ...
EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report [0.03%]
奥希替尼成功治疗经自然演变的伴神经内分泌分化的小细胞肺癌和肺腺癌病例报告：病例报告
Sho Takuma,Yusuke Inoue,Masato Karayama et al.
Sho Takuma et al.
Lineage transformation from lung adenocarcinoma (LUAD) to SCLC is associated with resistance to EGFR tyrosine kinase inhibitors. In addition to loss of p53 and RB, transformed SCLCs are usually not dependent on EGFR signaling, which renders...
Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report [0.03%]
阿特朱单抗联合化疗治疗肺腺癌合并自身抗体患者的疾病消退及伴随产生的自身免疫性溶血性贫血和噬血细胞性淋巴组织细胞增生症的病例报告
Yoshinari Endo,Yusuke Inoue,Masato Karayama et al.
Yoshinari Endo et al.
Various immune-related adverse events can frequently occur, which may be life-threatening if programmed death 1 or its ligand is blocked. Here, we report a rare case of concomitant autoimmune hemolytic anemia and hemophagocytic lymphohistio...
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC [0.03%]
Telisotuzumab Vedotin与Nivolumab联合治疗NSCLC的Ib期临床试验
D Ross Camidge,Fabrice Barlesi,Jonathan W Goldman et al.
D Ross Camidge et al.
Introduction: Telisotuzumab vedotin (Teliso-V) is an anti-c-Met-directed antibody-drug conjugate that has exhibited antitumor activity as monotherapy in NSCLC. Its potential activity combined with programmed cell death pr...
Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report [0.03%]
奥希替尼治疗EGFR突变型非小细胞肺癌患者的致死性肌炎病例报告
Fionnuala Crowley,Bailey G Fitzgerald,Aarti S Bhardwaj et al.
Fionnuala Crowley et al.
Osimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis hav...
Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC [0.03%]
BI 695502联合化疗对比贝伐珠单抗原研药联合化疗治疗晚期非鳞状细胞非小细胞肺癌患者的III期临床试验
Edward S Kim,Sigrid Balser,Klaus B Rohr et al.
Edward S Kim et al.
Introduction: Biological therapies such as bevacizumab have improved survival in patients with NSCLC. This study was conducted to confirm the equivalent efficacy of the biosimilar candidate BI 695502 to the bevacizumab re...
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations [0.03%]
针对KRAS突变型非小细胞肺癌患者的 trametinib和ponatinib一期临床试验
Kathryn C Arbour,Eusebio Manchado,Matthew J Bott et al.
Kathryn C Arbour et al.
Introduction: Somatic KRAS mutations occur in 25% of patients with NSCLC. Treatment with MEK inhibitor monotherapy has not been successful in clinical trials to date. Compensatory activation of FGFR1 was identified as a m...
Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study [0.03%]
基于EGFR基因突变状态的中国肺腺癌完全切除患者预后研究（ICAN研究）
Xue-Ning Yang,Hong-Hong Yan,Jun Wang et al.
Xue-Ning Yang et al.
Introduction: The adjuvant treatment of patients with resected lung adenocarcinoma (LUAD) remains unstandardized. We analyzed the survival outcomes of these patients based on EGFR mutation status and adjuvant chemotherapy...
Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer [0.03%]
新冠肺炎疫情对全球肺癌临床试验的影响：为何这会对肺癌患者产生影响
Upal Basu Roy,Anne-Marie Baird,Andrew Ciupek et al.
Upal Basu Roy et al.